We are live on ! Find out more
CBPO

China Biologic Products Holdings, Inc.
CBPO

Delisted

CBPO was delisted on the 20th of April, 2021.

162 hedge funds and large institutions have $3.22B invested in China Biologic Products Holdings, Inc. in 2016 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 60 increasing their positions, 44 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 18

55% more capital invested

Capital invested by funds: $2.08B → $3.22B (+$1.15B)

36% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 44

17% more funds holding

Funds holding: 138162 (+24)

14% more funds holding in top 10

Funds holding in top 10: 78 (+1)

24% less call options, than puts

Call options by funds: $18.3M | Put options by funds: $24.1M

Holders
162
Holders Change
+24
Holders Change %
+17.39%
% of All Funds
4.32%
Holding in Top 10
8
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+14.29%
% of All Funds
0.21%
New
42
Increased
60
Reduced
44
Closed
18
Calls
$18.3M
Puts
$24.1M
Net Calls
-$5.85M
Net Calls Change
-$5.14M
Name Holding Trade Value Shares
Change
Change in
Stake
WP
1
Warburg Pincus
New York
$831M -$154M -1,305,526 -99%
Capital Research Global Investors
2
Capital Research Global Investors
California
$389M +$11.1M +94,231 +3%
Capital World Investors
3
Capital World Investors
California
$296M -$60M -508,307 -18%
Baillie Gifford & Co
4
Baillie Gifford & Co
United Kingdom
$180M -$2.08M -17,600 -1%
Fidelity Investments
5
Fidelity Investments
Massachusetts
$164M -$11.3M -95,954 -7%
Invesco
6
Invesco
Georgia
$130M +$8.3M +70,338 +7%
Fidelity International
7
Fidelity International
Bermuda
$87.7M +$51.4M +435,581 +162%
Bank of New York Mellon
8
Bank of New York Mellon
New York
$66.9M +$3.53M +29,888 +6%
Mirae Asset Global Investments
9
Mirae Asset Global Investments
South Korea
$54.6M +$4.78M +40,481 +10%
BFA
10
BlackRock Fund Advisors
California
$44.5M +$1.97M +16,680 +5%
HIM
11
Hermes Investment Management
United Kingdom
$40M +$6.45M +54,641 +20%
CCMH
12
Cornerstone Capital Management Holdings
New York
$37.1M +$35.2M +298,168 New
DKCM
13
Davidson Kempner Capital Management
New York
$33.6M +$1.89M +16,000 +6%
Renaissance Technologies
14
Renaissance Technologies
New York
$32.6M +$3.91M +33,100 +14%
ICP
15
Indus Capital Partners
New York
$30.5M -$12.3M -103,973 -30%
ACM
16
Ariose Capital Management
Hong Kong
$27.7M +$28.2M +238,841 New
Norges Bank
17
Norges Bank
Norway
$26.9M +$2.36M +19,950 +10%
AllianceBernstein
18
AllianceBernstein
Tennessee
$26.7M +$22.8M +193,302 +930%
Ninety One (UK)
19
Ninety One (UK)
United Kingdom
$25M +$468K +3,963 +2%
BIT
20
BlackRock Institutional Trust
California
$24.8M +$11.8M +99,596 +100%
Ameriprise
21
Ameriprise
Minnesota
$24M +$393K +3,331 +2%
WA
22
Wasatch Advisors
Utah
$23.4M -$194K -1,644 -0.9%
AIM
23
abrdn Investment Management
United Kingdom
$22.9M +$4.18M +35,387 +24%
UBS AM
24
UBS AM
Illinois
$22.2M -$2.74M -23,195 -12%
BG
25
BlackRock Group
United Kingdom
$21.9M -$8.87M -75,171 -30%

CBPO Hedge Fund Activity: Q3 2016 in Review

162 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in China Biologic Products Holdings, Inc. (CBPO) for Q3 2016, worth a combined $3.22B — up 55% from $2.08B a quarter earlier.

Buyers outnumbered sellers: 42 funds opened new CBPO positions and 18 closed out — a net gain of 24 holders — while 60 added to existing stakes and 44 trimmed.

The largest buyer was Fidelity International, adding an estimated $51.4M. The largest seller was Warburg Pincus, cutting an estimated $154M.

  • 162 institutional investors held China Biologic Products Holdings, Inc. (CBPO) as of Q3 2016, up from 138 in Q2 2016.
  • Funds reported $3.22B of China Biologic Products Holdings, Inc. stock for Q3 2016, up 55% quarter-over-quarter.
  • 42 funds opened new China Biologic Products Holdings, Inc. positions in Q3 2016 and 18 closed out, a net change of +24 holders.
  • The largest China Biologic Products Holdings, Inc. buyer in Q3 2016 was Fidelity International, an estimated $51.4M added.
  • The largest China Biologic Products Holdings, Inc. seller in Q3 2016 was Warburg Pincus, an estimated $154M sold.

Based on aggregated 13F filings for Q3 2016.